Prophylactic B. velezensis HBXN2020 spores attenuated the symptoms of S. Typhimurium-infected mouse.
(A) Experimental design for treatment in this study. At days 1, 3, 5, and 7, each mouse in the HBXN2020+STm group, CIP+STm group, and PBS+STm group were received 200 μL of B. velezensis HBXN2020 spores (1×108 CFU/mouse), ciprofloxacin or sterile PBS by gavage, respectively. Then, mice in PBS+STm group, HBXN2020+STm group and CIP+STm group were orally inoculated with 200 μL (5×107 CFU/mouse) of STm on day 7, respectively. On day 12, all mice were euthanized. (B) Daily body weight changes and (C) daily disease activity index (DAI) scores of mice with different groups following STm treatment. Data were shown as mean values ± SEM (n = 6). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p < 0.05, **, p < 0.01, and ***, p < 0.001). (D) Colonic tissue images. (E) The length of the colon from per group (n = 6). (F) Bacterial count of STm in mouse feces. Fecal samples were collected every day after STm infection and resuspended in sterile PBS (0.1 g of fecal resuspended in 1 mL of sterile PBS). One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates (50 µg mL-1 kanamycin) and incubated at 37°C for 12[h before bacterial counting. The bacterial loads of STm in (G) cecum and (H) colon. The cecum and colon were harvested and then homogenized. Statistical signifcance was evaluated using Student’s t-test (*, p < 0.05, **, p < 0.01, and ***, p < 0.001).